In a 15-month prospective study...

LUMASON® ultrasound enhancing agent was administered 2,137 times with no reports of back pain.1*

In pivotal trials…
Most adverse reactions were mild to moderate in intensity and resolved spontaneously.2
LUMASON STUDY RESULTS1

2,137
Doses

15
Months

0
Reports of Back Pain

Study Image

* Based on a single-center study of adult patients (age >18 years) receiving a UEA (LUMASON®, Optison®, or Definity®) were prospectively evaluated for clinically significant adverse events defined as either anaphylactoid reactions (rash, flank pain, dyspnea, and wheeze) or true anaphylaxis. Study objectives included the following: determining the major adverse reactions experienced by patients receiving UEA in a clinical setting, assessing whether microbubbles are safe for use in patients with intra-cardiac shunts, and assessing whether the types of adverse reactions differ significantly among the three FDA-approved UEAs.

Learn more today!

Contact your LUMASON Account Manager to learn more about our multiple indications and our safety

Thank you for contacting us!

One of our Account Managers will be following up with you shortly.

Failed to submit!

Please check your connection and try again.

Service unavailable!

Please check your connection and try again.
User Profile

The individual who appears is for illustrative purposes only. All persons depicted are models and not real patients.